STSander W. Tas

Sander W. Tas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sander W. Tas has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Chrissta X. Maracle

    Amsterdam Rheumatology and Immunology Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Laboratory for Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

    5 shared publications
  • Boy Helder

    Amsterdam Rheumatology and Immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

    4 shared publications
  • Paul P. Tak

    4 shared publications
  • Katinka P.M. van Zoest

    2 shared publications
  • Paul Peter Tak

    Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

    2 shared publications
  • A. Al-Soudi

    Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

    by A. Al-Soudi, M. E. Doorenspleet, R. E. Esveldt, L. T. Burgemeister, A. E. Hak, B. J. H. van Den Born, S. W. Tas, R. F. van Vollenhoven, P. L. Klarenbeek, N. de Vries

    An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1–2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. The median qPCR score was higher in active GPA (21.4; IQR 12.1–29.6) than in remission/LDA (3.3; IQR 1.6–5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA.


  • Open Access

    Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups

    by on behalf of EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group, Aurélie Najm, Benoît Le Goff, Carl Orr, Rogier Thurlings, Juan D. Cañete, Frances Humby, Stefano Alivernini, Antonio Manzo, Søren Andreas Just, et al.

    The aim of this global collaboration was to develop a consensual set of items for the analysis of synovial biopsies in clinical practice and translational research through the EULAR Synovitis Study Group (ESSG) and OMERACT Synovial Tissue Biopsy Group. Participants were consulted through a modified Delphi method. Three sequential rounds occurred over 12 months. Members were sent a written questionnaire containing items divided into two parts. Items were identified and formulated based on a scoping review. The first part of the questionnaire referred to synovial biopsies in clinical practice including five subsections, and the second part to translational research with six subsections. Every participant was asked to score each item on a 5-point Likert scale. Items with a median score above 3.5 and a ≥ 70% agreement were selected for the next round. The last round was conducted orally at EULAR in June 2017. Twenty-seven participants from 19 centers were contacted by email. Twenty participants from 17 centers answered. Response rates for next rounds were 100%. For the first part relating to clinical practice, 20/44 items (45.5%) were selected. For the second part relating to translational research, 18/43 items (41.9%) were selected for the final set. We herein propose a consensual set of analysis items to be used for synovial biopsies conducted in clinical practice and translational research.


  • Open Access

    Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis

    by Chrissta X. Maracle, Kim C.M. Jeucken, Boy Helder, Thomas M. van Gulik, Anne Steins, Hanneke W.M. van Laarhoven, Sander W. Tas

    Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis


  • Open Access

    Noncanonical NF-κB signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction

    by Chrissta X. Maracle, Rabia Agca, Boy Helder, John A.L. Meeuwsen, Hans W.M. Niessen, Erik A.L. Biessen, Menno P.J. de Winther, Saskia C.A. de Jager, Mike T. Nurmohamed, Sander W. Tas


  • Open Access

    How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?

    by Anne Musters, Sander W Tas

    Making the right clinical decisions for rare diseases with the right tools


  • Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis

    by Chrissta X. Maracle, Paulina Kucharzewska, Boy Helder, Corine van der Horst, Pedro Correa de Sampaio, Ae-Ri Noort, Katinka van Zoest, Arjan W. Griffioen, Henric Olsson, Sander W. Tas

    Objective. Angiogenesis is crucial in RA disease progression. Lymphotoxin β receptor (LTβR)-induced activation of the non-canonical nuclear factor-κB (NF-κB) pathway via NF-κB-inducing kinase (NIK) has been implicated in this process. Consequently, inhibition of this pathway may hold therapeutic potential in RA. We describe a novel three-dimensional (3D) model of synovial angiogenesis incorporating endothelial cells (ECs), RA fibroblast-like synoviocytes (RAFLSs) and RA synovial fluid (RASF) to further investigate the contributions of NF-κB in this process. Methods. Spheroids consisting of RAFLSs and ECs were stimulated with RASF, the LTβR ligands LTβ and LIGHT, or growth factor bFGF and VEGF, followed by quantification of EC sprouting using confocal microscopy and digital image analysis. Next, the effects of anginex, NIK-targeting siRNA (siNIK), LTβR–Ig fusion protein (baminercept) and a novel pharmacological NIK inhibitor were investigated. Results. RASF significantly promoted sprout formation, which was blocked by the established angiogenesis inhibitor anginex (P < 0.05). LTβ and LIGHT induced significant sprouting (P < 0.05), as did bFGF/VEGF (P < 0.01). siNIK pre-treatment of ECs led to reductions in LTβR-induced vessel formation (P < 0.05). LTβR–Ig not only blocked LTβ- or LIGHT-induced sprouting, but also RASF-induced sprouting (P < 0.05). The NIK inhibitor blocked angiogenesis induced by LTβ, LIGHT, growth factors (P < 0.05) and RASF (P < 0.01). Conclusion. We present a novel 3D model of synovial angiogenesis incorporating RAFLSs, ECs and RASF that mimics the in vivo situation. Using this system, we demonstrate that non-canonical NF-κB signalling promotes neovascularization and show that this model is useful for dissecting relative contributions of signalling pathways in specific cell types to angiogenic responses and for testing pharmacological inhibitors of angiogenesis.


  • Nuclear Factor-κB–inducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study

    by Karen I. Maijer, Ae Ri Noort, Maria J.H. de Hair, Christiaan van der Leij, Katinka P.M. van Zoest, Ivy Y. Choi, Daniëlle M. Gerlag, Mario Maas, Paul P. Tak, Sander W. Tas

    Objective.: The nuclear factor-κB (NF-κB) family of transcription factors is strongly involved in synovial inflammation. We have previously shown that NF-κB–inducing kinase (NIK) is a key regulator of inflammation-induced angiogenesis in rheumatoid arthritis (RA) synovial tissue (ST). Here, we investigated synovial NIK expression in patients with early arthritis and in autoantibody-positive individuals at risk of developing RA.Methods.: ST biopsies were obtained by arthroscopy from 154 patients with early arthritis (duration < 1 yr) with various diagnoses and 54 IgM rheumatoid factor–positive and/or anticitrullinated protein antibodies–positive individuals without evidence of arthritis. ST was stained for NIK and endothelial cell (EC) markers. Additionally, measures of disease activity were collected and contrast-enhanced magnetic resonance imaging (MRI) was performed in a subset of these patients.Results.: In patients with early arthritis, NIK was predominantly expressed in EC of small blood vessels. Further, NIK expression correlated with erythrocyte sedimentation rate (r 0.184, p = 0.024), C-reactive protein (r 0.194, p = 0.017), joint swelling (r 0.297, p < 0.001), synovial immune cell markers (lining r 0.585, p < 0.001; sublining macrophages r 0.728, p < 0.001; T cells r 0.733, p < 0.001; and B cells r 0.264, p = 0.040), MRI effusion (r 0.665, p < 0.001), MRI synovitis (r 0.632, p < 0.001), and MRI total score (r 0.569, p < 0.001). In 18.5% of autoantibody-positive individuals, ST NIK+EC were present, but this was not predictive of the development of arthritis.Conclusion.: NIK+EC are present in the earliest phase of synovial inflammation and may be indicative of high angiogenic activity in the inflamed ST. Therefore, NIK+EC may play an important role in the persistence of synovitis. Collectively, our data underscore the importance of angiogenesis in synovial inflammation and identify NIK as a potential therapeutic target in arthritis.


  • Tertiary Lymphoid Structures in Rheumatoid Arthritis

    by Ae R. Noort, Katinka P.M. van Zoest, Lisa G. van Baarsen, Chrissta X. Maracle, Boy Helder, Natalie Papazian, Monica Romera-Hernandez, Paul P. Tak, Tom Cupedo, Sander W. Tas


  • The contribution of NF‐κB signalling to immune regulation and tolerance

    by Myrthe A M Van Delft, Leonie F A Huitema, Sander W Tas

    Background: Immune regulation is necessary to control inflammatory responses and to prevent autoimmune diseases. Therefore, mechanisms of central and peripheral tolerance have evolved to ensure that T cells recognize antigens as self‐ or non‐self‐antigens. The thymus is crucially important for central tolerance induction to self‐antigens via negative selection of T cells. However, if T cells escape negative selection in the thymus and enter the periphery, peripheral mechanisms are active to warrant immune tolerance. Secondary lymphoid organs, as well as tolerogenic dendritic cells and regulatory T cells, play an important role in peripheral tolerance. In chronic inflammatory diseases, tertiary lymphoid organs are sometimes formed that may also be involved in the induction of peripheral tolerance. This review discusses the main processes that are involved in immune regulation and tolerance, and focuses on the contribution of NF‐κB signalling to these processes.Material and methods: This narrative review is based on peer‐reviewed publications listed on PubMed up to December 2014. The focus of our literature search was on studies investigating the role of (non)canonical NF‐κB signalling in central and peripheral mechanisms of tolerance. Only studies published in English language were considered.Results: This review discusses the immune phenotype of mutant mice with defective (non)canonical NF‐κB signalling, corroborated with human data, and emphasizes the contribution of the noncanonical NF‐κB pathway to immune regulation and tolerance induction.Conclusions: Noncanonical NF‐κB signalling has an important immunoregulatory role in the immune system and contributes to both central and peripheral mechanisms of tolerance.